Last reviewed 2026-04-20 · How we verify

Vemurafenib plus Cobimetinib (combination) (vemurafenib-plus-cobimetinib-combination)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Diarrhoea
• Nausea
• Fatigue
• Anaemia
• Rash
• Arthralgia
• Decreased appetite
• Pyrexia
• Vomiting
• Asthenia
• Neutropenia
• Constipation

Key clinical trials

• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
• A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
• Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (PHASE3)
• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. (PHASE2, PHASE3)
• DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol (PHASE2, PHASE3)
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (PHASE2)
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Vemurafenib plus Cobimetinib (combination) CI brief — competitive landscape report
• Vemurafenib plus Cobimetinib (combination) updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI